Journal Article

The German Chronic Kidney Disease (GCKD) study: design and methods

Kai-Uwe Eckardt, Barbara Bärthlein, Seema Baid-Agrawal, Andreas Beck, Martin Busch, Frank Eitner, Arif B. Ekici, Jürgen Floege, Olaf Gefeller, Hermann Haller, Robert Hilge, Karl F. Hilgers, Jan T. Kielstein, Vera Krane, Anna Köttgen, Florian Kronenberg, Peter Oefner, Hans-Ulrich Prokosch, André Reis, Matthias Schmid, Elke Schaeffner, Ulla T. Schultheiss, Susanne A. Seuchter, Thomas Sitter, Claudia Sommerer, Gerd Walz, Christoph Wanner, Gunter Wolf, Martin Zeier and Stephanie Titze

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 27, issue 4, pages 1454-1460
Published in print April 2012 | ISSN: 0931-0509
Published online August 2011 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfr456
The German Chronic Kidney Disease (GCKD) study: design and methods

Show Summary Details

Preview

Background.

Chronic kidney disease (CKD) is increasingly recognized as a global health problem. The conditions leading to CKD, the health impact of CKD and the prognosis differ markedly between affected individuals. In particular, renal failure and cardiovascular mortality are competing risks for CKD patients. Opportunities for targeted intervention are very limited so far and require an improved understanding of the natural course of CKD, of the risk factors associated with various clinical end points and co-morbidities as well as of the underlying pathogenic mechanisms.

Methods.

The German Chronic Kidney Disease (GCKD) study is a prospective observational national cohort study. It aims to enrol a total of 5000 patients with CKD of various aetiologies, who are under nephrological care, and to follow them for up to 10 years. At the time of enrolment, male and female patients have an estimated glomerular filtration rate (eGFR) of 30–60 mL/min × 1.73m2 or overt proteinuria in the presence of an eGFR >60 mL/min × 1.73m2. Standardized collection of biomaterials, including DNA, serum, plasma and urine will allow identification and validation of biomarkers associated with CKD, CKD progression and related complications using hypothesis-driven and hypothesis-free approaches. Patient recruitment and follow-up is organized through a network of academic nephrology centres collaborating with practising nephrologists throughout the country.

Conclusions.

The GCKD study will establish one of the largest cohorts to date of CKD patients not requiring renal replacement therapy. Similarities in its design with other observational CKD studies, including cohorts that have already been established in the USA and Japan, will allow comparative and joint analyses to identify important ethnic and geographic differences and to enhance opportunities for identification of relevant risk factors and markers.

Keywords: biomarkers; cohort; epidemiology; prognosis; risk factors

Journal Article.  4252 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.